amylin   Click here for help

GtoPdb Ligand ID: 687

Abbreviated name: AMY
Comment: Amylin acts as an appetite suppressor. Novo Nordisk have a long-acting amylin mimetic (AM833, NNC0174-0833) in clinical trials with and without semaglutide. AM833 is intended as a treatment for obesity. In the trials it is administered subcutaneously, once-weekly. Preliminary (and as yet unpublished) results from a Phase 2 trial as monotherapy demonstrated weight loss of 10.8% at week 26, meeting the study's primary endpoint (Novo Nordisk press release 18 Jun 2020).
Species: Human
Click here for help
References
1. Gingell JJ, Burns ER, Hay DL. (2014)
Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Endocrinology, 155 (1): 21-6. [PMID:24169554]
2. Muff R, Bühlmann N, Fischer JA, Born W. (1999)
An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3.
Endocrinology, 140 (6): 2924-7. [PMID:10342886]
3. Zimmermann U, Fluehmann B, Born W, Fischer JA, Muff R. (1997)
Coexistence of novel amylin-binding sites with calcitonin receptors in human breast carcinoma MCF-7 cells.
J. Endocrinol., 155 (3): 423-31. [PMID:9487987]